BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong CW, Metselaar JM, Storm G, Wong TT. A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. Br J Ophthalmol. [DOI: 10.1136/bjophthalmol-2020-315911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Harrell CR. Therapeutic Potential of d-MAPPS™ for Ocular Inflammatory Diseases and Regeneration of Injured Corneal and Retinal Tissue. IJMS 2022;23:13528. [DOI: 10.3390/ijms232113528] [Reference Citation Analysis]
2 Afarid M, Mahmoodi S, Baghban R. Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update. J Nanobiotechnology 2022;20:361. [PMID: 35918688 DOI: 10.1186/s12951-022-01567-7] [Reference Citation Analysis]
3 Kagkelaris K, Panayiotakopoulos G, Georgakopoulos CD. Nanotechnology-based formulations to amplify intraocular bioavailability. Ophthalmol Eye Dis 2022;14:251584142211123. [DOI: 10.1177/25158414221112356] [Reference Citation Analysis]
4 Gómez-Aguado I, Rodríguez-Castejón J, Beraza-Millor M, Vicente-Pascual M, Rodríguez-Gascón A, Garelli S, Battaglia L, Del Pozo-Rodríguez A, Solinís MÁ. mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation. Pharmaceutics 2021;13:1472. [PMID: 34575548 DOI: 10.3390/pharmaceutics13091472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Xing Y, Zhu L, Zhang K, Li T, Huang S. Nanodelivery of triamcinolone acetonide with PLGA-chitosan nanoparticles for the treatment of ocular inflammation. Artif Cells Nanomed Biotechnol 2021;49:308-16. [PMID: 33739906 DOI: 10.1080/21691401.2021.1895184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]